ClinicalTrials.gg
CompletedNCT06625307Updated Jun 22, 2026

A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin

A Phase 1 interventional study of NNC0537-1482 and Placebo in Healthy Volunteers and Heart Failure, sponsored by Novo Nordisk A/S. Completed at 1 site in Netherlands. Open to participants aged 22 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
22 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Heart Failure by Novo Nordisk A/S — 5 open to participants now, 6 under way, 2 of them phase 3. Heart Failure · Novo Nordisk A/S.

Enrollment
9th of 11
31 · median 200
Started
2024
with 2 others
Phase 1
4 of 14
2 open now
Registered
7th of 14
by date

Among the 14 studies in Heart Failure by Novo Nordisk A/S, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 in phase 1, and was the 7th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 22 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The study is testing a new medicine to potentially treat people with heart failure. The main purpose of the study is to see if the new study medicine is safe and how it works in the body. It is the first time NNC0537-1482 (the new study medicine) is tested in humans and will be tested in healthy individuals (men and postmenopausal women). Participant will either get NNC0537-1482 or placebo (a "dummy medicine" without any active ingredients). Which treatment the participant get is decided by chance and the participant will only get either the study medicine or placebo on one occasion. It will be injected under the skin of the stomach by the study staff and the number of injections will depend on the cohort participant is assigned to. NNC0537-1482 cannot be prescribed by doctors. The study consists of 6 cohorts (groups) with 6 different dosing levels. The study will last for about 9 months. Participation in the study will last up to 42 days (depending on the cohort participant are assigned to) with an additional screening period that can be up to 28 days. Participant will have up to 10 visits to the clinic during the study period. However, the total number of visits depend on which cohort participant is assigned to.

03

Conditions studied

  • Healthy Volunteers
  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
22 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age 22-55 years (both inclusive) at the time of signing the .
  • (BMI) between 18.5 and 30.0 kilogram/meter per square (kg/m\^2) (both inclusive) at screening.
  • Considered eligible and generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Use of prescription or non-prescription medicinal products, including herbal medications, within 14 days before screening. Occasional use of over-the-counter vitamins, or paracetamol or Non-steroidal anti-inflammatory drugs (NSAIDs) at their labelled doses for mild pain is permitted.
  • Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Orthostatic hypotension, defined as a decrease in systolic blood pressure greater than or equal to 20 millimetres of mercury (mmHg) or a decrease in diastolic blood pressure greater than or equal to 10 (mmHg) from supine to standing after 3 minutes, at the screening visit.
  • Any laboratory safety parameters at screening outside the below laboratory ranges for:

    • (ALT) greater than (>) Upper normal limits (UNL) plus (+) 10 Percentage (%)
    • Aspartate Aminotransferase (AST) > Upper limit normal () +20%
    • > ULN + 20%
    • Creatinine > ULN + 10%
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    NNC0537-1482 Dose level 1

    Participants will be administered a single dose of dose level 1 of NNC0537-1482 subcutaneously.

    Drug: NNC0537-1482 · Drug: Placebo

  • Experimental
    NNC0537-1482 Dose level 2

    Participants will be administered a single dose of dose level 2 of NNC0537-1482 subcutaneously.

    Drug: NNC0537-1482 · Drug: Placebo

  • Experimental
    NNC0537-1482 Dose level 3

    Participants will be administered a single dose of dose level 3 of NNC0537-1482 subcutaneously.

    Drug: NNC0537-1482 · Drug: Placebo

  • Experimental
    NNC0537-1482 Dose level 4

    Participants will be administered a single dose of dose level 4 of NNC0537-1482 subcutaneously.

    Drug: NNC0537-1482 · Drug: Placebo

  • Experimental
    NNC0537-1482 Dose level 5

    Participants will be administered a single dose of dose level 5 of NNC0537-1482 subcutaneously.

    Drug: NNC0537-1482 · Drug: Placebo

  • Experimental
    NNC0537-1482 Dose level 6

    Participants will be administered a single dose of dose level 6 of NNC0537-1482 subcutaneously.

    Drug: NNC0537-1482 · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will be administered a single dose of Placebo matched to NNC0537-1482 subcutaneously

    Drug: Placebo

Interventions

  • Administered via subcutaneous route

  • DrugPlacebo

    Administered via subcutaneous route

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAE) in cohorts 1 and 2

    Number of events.

    Time frame: From pre-dose on Day 1 until completion of the End of study visit (V10) at Day 15

  2. Number of treatment emergent adverse events (TEAE) in cohort 3

    Number of events.

    Time frame: From pre-dose on Day 1 until completion of the End of study visit (V10) at Day 22

  3. Number of treatment emergent adverse events (TEAE) in cohorts 4, 5 and 6

    Number of events.

    Time frame: From pre-dose on Day 1 until completion of the End of study visit (V10) at Day 40

07

Study locations

1 site
  • ICON - location Groningen
    Groningen, 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in May 2025, 7 months.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 7 months is close to that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2024
First posted
Oct 3, 2024
StartActual
Oct 3, 2024
Primary completionActual
May 4, 2025
CompletionActual
May 4, 2025
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06625307
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Oct 3, 2024
Primary completion
May 4, 2025
Completion
May 4, 2025
Last update
Jun 22, 2026

Study contacts

Clinical Transparency '(dept. 2834)'
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0537-1482

Start the discussion